The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global asthma therapeutics market was valued at US$ 17.6 Billion in 2020.
We expect the global asthma therapeutics market to exhibit a CAGR of 1.60% during 2021-2026.
The increasing prevalence of asthma, along with continuous improvements in the diagnostic technologies, are driving the global asthma therapeutics market.
Sudden outbreak of the COVID-19 pandemic has led to the increasing adoption of asthma therapeutics as severe respiratory diseases, such as coronavirus infection, can worsen asthma symptoms.
Based on the drug class, the global asthma therapeutics market can be segmented into anti-inflammatory drugs, bronchodilators, and combination therapies. Currently, combination therapies hold the majority of the total market share.
Based on the product type, the global asthma therapeutics market has been segregated into inhalers and nebulizers where, nebulizers currently represent the largest segment.
Based on the route of administration, the global asthma therapeutics market can be segmented into inhalation, oral and parenteral. Among these, inhalation accounts for the largest market share.
On a regional level, the market has been classified into North America, Asia Pacific, Europe, Latin America, and Middle East and Africa, where North America currently dominates the global market.
Some of the major players in the global asthma therapeutics market include AstraZeneca, Abbott, Amgen Inc., Biogen Inc., Boehringer Ingelheim GmbH, F. Hoffmann-La Roche AG, GlaxoSmithKline plc., Merck & Co. Inc., Novartis AG, Sunovion Pharmaceuticals Inc. (Dainippon Sumitomo Pharma Co. Ltd.) and Teva Pharmaceutical Industries Ltd.
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at